Oak Ridge native Chris Jones shares his journey from studying nuclear engineering to becoming a heart surgeon and writing a new book.

Despite the headline miss, Axoltis Chief Medical Officer Annette Janus, M.D., described the results as "promising." Axoltis Pharma's phase 2 trial for amyotrophic lateral sclerosis (ALS) may have ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating ...

Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...

CD40 agonist mitazalimab + mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final efficacy analysis of the OPTIMIZE-1 study. This is an ASCO Meeting Abstract ...

“Suzetrigine has again demonstrated its potential to fill an important unmet need in the treatment of pain. Today's LSR results are consistent with previous studies of this pain signal inhibitor in ...

Techniques and applications of integration. An introduction to multi-variable calculus: partial derivatives and double integrals. Prerequisite: MATH 1212 or MATH 1234. Fundamentals of Calculus II is ...

The vice president of U.S. medical affairs and global at Eli Lilly and Company discussed how a subgroup of patients treated with donanemab maintained cognitive benefit for 2 years. [WATCH TIME: 5 ...

At ESMO 2025, Nima Nabavizadeh presented PATHFINDER II study during Proffered Paper Session 1 on Basic science & Translational research, outlining the study’s design, safety profile, and performance ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...